JP2018522579A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522579A5 JP2018522579A5 JP2018512825A JP2018512825A JP2018522579A5 JP 2018522579 A5 JP2018522579 A5 JP 2018522579A5 JP 2018512825 A JP2018512825 A JP 2018512825A JP 2018512825 A JP2018512825 A JP 2018512825A JP 2018522579 A5 JP2018522579 A5 JP 2018522579A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- supernatant
- cell culture
- level
- vitro cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006228 supernatant Substances 0.000 claims description 122
- 238000000034 method Methods 0.000 claims description 108
- 238000012606 in vitro cell culture Methods 0.000 claims description 92
- 239000003112 inhibitor Substances 0.000 claims description 65
- 230000011664 signaling Effects 0.000 claims description 61
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 32
- 210000003013 erythroid precursor cell Anatomy 0.000 claims description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 229920001184 polypeptide Polymers 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- -1 Bcl-xL Proteins 0.000 claims description 14
- 210000002536 stromal cell Anatomy 0.000 claims description 13
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims description 12
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims description 10
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 10
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 10
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 10
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims description 10
- 102000003952 Caspase 3 Human genes 0.000 claims description 10
- 108090000397 Caspase 3 Proteins 0.000 claims description 10
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 10
- 102100031785 Endothelial transcription factor GATA-2 Human genes 0.000 claims description 10
- 102100031690 Erythroid transcription factor Human genes 0.000 claims description 10
- 102100035716 Glycophorin-A Human genes 0.000 claims description 10
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 10
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 claims description 10
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 claims description 10
- 101001066265 Homo sapiens Endothelial transcription factor GATA-2 Proteins 0.000 claims description 10
- 101001066268 Homo sapiens Erythroid transcription factor Proteins 0.000 claims description 10
- 101001074244 Homo sapiens Glycophorin-A Proteins 0.000 claims description 10
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 10
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 10
- 101000621061 Homo sapiens Serum paraoxonase/arylesterase 2 Proteins 0.000 claims description 10
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 10
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 10
- 108090000174 Interleukin-10 Proteins 0.000 claims description 10
- 108010002350 Interleukin-2 Proteins 0.000 claims description 10
- 108090001005 Interleukin-6 Proteins 0.000 claims description 10
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 10
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 10
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims description 10
- 102100022824 Serum paraoxonase/arylesterase 2 Human genes 0.000 claims description 10
- 102000000763 Survivin Human genes 0.000 claims description 10
- 108010002687 Survivin Proteins 0.000 claims description 10
- 208000005980 beta thalassemia Diseases 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 10
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 9
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims description 9
- 108090001007 Interleukin-8 Proteins 0.000 claims description 9
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 8
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 8
- 108020001507 fusion proteins Proteins 0.000 claims description 8
- 102000037865 fusion proteins Human genes 0.000 claims description 8
- 230000035755 proliferation Effects 0.000 claims description 8
- 239000003636 conditioned culture medium Substances 0.000 claims description 6
- 102000005606 Activins Human genes 0.000 claims description 5
- 108010059616 Activins Proteins 0.000 claims description 5
- 101000941598 Homo sapiens Complement C5 Proteins 0.000 claims description 5
- 239000000488 activin Substances 0.000 claims description 5
- 108010031102 heme oxygenase-2 Proteins 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 239000012228 culture supernatant Substances 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- 108060004872 MIF Proteins 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 7
- 210000001956 EPC Anatomy 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 102000034655 MIF Human genes 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021158571A JP2022023072A (ja) | 2015-05-20 | 2021-09-29 | アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562164367P | 2015-05-20 | 2015-05-20 | |
| US62/164,367 | 2015-05-20 | ||
| US201662320032P | 2016-04-08 | 2016-04-08 | |
| US62/320,032 | 2016-04-08 | ||
| PCT/US2016/033187 WO2016187378A1 (en) | 2015-05-20 | 2016-05-19 | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021158571A Division JP2022023072A (ja) | 2015-05-20 | 2021-09-29 | アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522579A JP2018522579A (ja) | 2018-08-16 |
| JP2018522579A5 true JP2018522579A5 (OSRAM) | 2019-06-27 |
Family
ID=57320751
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512825A Pending JP2018522579A (ja) | 2015-05-20 | 2016-05-19 | アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法 |
| JP2021158571A Pending JP2022023072A (ja) | 2015-05-20 | 2021-09-29 | アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021158571A Pending JP2022023072A (ja) | 2015-05-20 | 2021-09-29 | アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10548976B2 (OSRAM) |
| EP (2) | EP3298034A4 (OSRAM) |
| JP (2) | JP2018522579A (OSRAM) |
| CN (1) | CN108350057A (OSRAM) |
| CA (1) | CA2986432A1 (OSRAM) |
| HK (1) | HK1252174A1 (OSRAM) |
| MA (1) | MA42160A (OSRAM) |
| WO (1) | WO2016187378A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10195249B2 (en) | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| JP2018501307A (ja) | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| CA2986432A1 (en) | 2015-05-20 | 2016-11-24 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
| WO2017079591A2 (en) * | 2015-11-04 | 2017-05-11 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| WO2018089706A2 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| CN110099995A (zh) * | 2017-01-06 | 2019-08-06 | 奥林巴斯株式会社 | 细胞观察系统 |
| WO2019094751A1 (en) | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| KR20200109330A (ko) | 2018-01-12 | 2020-09-22 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법 |
| AU2019266314B2 (en) * | 2018-05-09 | 2025-05-15 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| JP7388679B2 (ja) * | 2019-05-28 | 2023-11-29 | 学校法人 東洋大学 | 熱中症マーカー及びその利用 |
| KR20230004515A (ko) * | 2020-03-20 | 2023-01-06 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 ii 키메라 및 이의 사용 방법 |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| WO2021222322A1 (en) * | 2020-04-28 | 2021-11-04 | Acceleron Pharma Inc. | Actrii proteins and use in treating post-capillary pulmonary hypertension |
| CN115989035A (zh) * | 2020-06-23 | 2023-04-18 | 阿塞勒隆制药公司 | 用于治疗肺动脉高压(pah)的actrii蛋白 |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| EP4240399A4 (en) * | 2020-11-06 | 2024-10-09 | Acceleron Pharma Inc. | FORMULATIONS WITH ACTRII POLYPEPTIDE VARIANTS |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000046349A1 (en) | 1999-02-04 | 2000-08-10 | Technion Research & Development Foundation Ltd. | Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells |
| JP2004526419A (ja) | 2000-10-16 | 2004-09-02 | フィロス インク． | 抗体模倣物および他の結合タンパク質のためのタンパク質骨格 |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2002088171A2 (en) | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| ES2426005T3 (es) | 2004-07-23 | 2013-10-18 | Acceleron Pharma Inc. | Polipéptidos del receptor ACTRII, procedimientos y composiciones |
| WO2006055689A2 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
| EP3811965A1 (en) | 2005-11-23 | 2021-04-28 | Acceleron Pharma, Inc. | Activin-actriia antagonists in use for promoting bone growth |
| UA116871C2 (uk) * | 2006-12-18 | 2018-05-25 | Акселерон Фарма Інк. | СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| EP2599495A1 (en) | 2007-02-01 | 2013-06-05 | Acceleron Pharma, Inc. | Activin-ActRIIa Antagonists and Uses for Treating or Preventing Breast Cancer |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| KR20200054317A (ko) | 2007-02-09 | 2020-05-19 | 악셀레론 파마 인코포레이티드 | 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도 |
| CA2699936A1 (en) | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| CA2729096C (en) | 2008-06-26 | 2020-04-28 | Acceleron Pharma Inc. | Methods for dosing an actriib antagonist and monitoring of treated patients |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| HUE051137T2 (hu) * | 2008-08-14 | 2021-03-01 | Acceleron Pharma Inc | GDF-csapdák |
| WO2010083034A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| US8178488B2 (en) | 2009-06-08 | 2012-05-15 | Acceleron Pharma, Inc. | Methods for increasing thermogenic adipocytes |
| EP2440577A4 (en) | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
| ES2844123T3 (es) * | 2009-08-13 | 2021-07-21 | Acceleron Pharma Inc | Uso combinado de trampas de GDF y activadores del receptor de la eritropoyetina para aumentar los niveles de glóbulos rojos |
| MX340451B (es) | 2009-09-09 | 2016-07-08 | Acceleron Pharma Inc | Antagonistas de actriib y dosificacion y usos de los mismos. |
| EP3260130B1 (en) | 2009-11-03 | 2021-03-10 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
| US8710016B2 (en) | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| CN107837390A (zh) * | 2011-10-17 | 2018-03-27 | 阿塞勒隆制药公司 | 用于治疗无效性红细胞生成的方法和组合物 |
| EP2911682A4 (en) | 2012-10-24 | 2016-03-23 | Celgene Corp | METHOD FOR TREATING ANEMIA |
| EP2912462B1 (en) | 2012-10-24 | 2019-08-07 | Celgene Corporation | Biomarker for use in treating anemia |
| US10195249B2 (en) | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| EP3808778A1 (en) | 2014-04-18 | 2021-04-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating sickle-cell disease |
| CN107135646B (zh) | 2014-06-13 | 2022-03-15 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| JP2018501307A (ja) | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| AU2016261913B2 (en) | 2015-05-13 | 2021-08-12 | Acceleron Pharma Inc. | Treatment of beta-thalassemia using ActRII ligand traps |
| CA2986432A1 (en) | 2015-05-20 | 2016-11-24 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
| WO2017079591A2 (en) | 2015-11-04 | 2017-05-11 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| US10550170B2 (en) | 2015-11-23 | 2020-02-04 | Acceleron Pharma Inc. | Methods for treating vascular eye disorders with actrii antagonists |
| SI3496739T1 (sl) | 2016-07-15 | 2021-06-30 | Acceleron Pharma Inc. | Sestave, ki zajemajo polipeptide actriia, za uporabo pri zdravljenju pljučne hipertenzije |
| AU2017302282B2 (en) | 2016-07-27 | 2024-07-25 | Acceleron Pharma Inc. | Methods and compositions for treating myelofibrosis |
| JP7496686B2 (ja) | 2017-06-14 | 2024-06-07 | セルジーン コーポレイション | 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法 |
-
2016
- 2016-05-19 CA CA2986432A patent/CA2986432A1/en active Pending
- 2016-05-19 US US15/574,897 patent/US10548976B2/en not_active Expired - Fee Related
- 2016-05-19 EP EP16797267.8A patent/EP3298034A4/en not_active Withdrawn
- 2016-05-19 JP JP2018512825A patent/JP2018522579A/ja active Pending
- 2016-05-19 CN CN201680042691.9A patent/CN108350057A/zh active Pending
- 2016-05-19 WO PCT/US2016/033187 patent/WO2016187378A1/en not_active Ceased
- 2016-05-19 EP EP22201847.5A patent/EP4190805A3/en not_active Withdrawn
- 2016-05-19 MA MA042160A patent/MA42160A/fr unknown
- 2016-05-19 HK HK18111575.0A patent/HK1252174A1/zh unknown
-
2019
- 2019-12-11 US US16/711,039 patent/US20200101157A1/en not_active Abandoned
-
2021
- 2021-09-29 JP JP2021158571A patent/JP2022023072A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522579A5 (OSRAM) | ||
| US12286477B2 (en) | Anti-TCR antibody molecules and uses thereof | |
| Madonna et al. | The significance of IL-36 hyperactivation and IL-36R targeting in psoriasis | |
| US11708392B2 (en) | Peptide conjugates | |
| US11584927B2 (en) | Conditionally active chimeric antigen receptors for modified T-cells | |
| ES2900233T3 (es) | Moléculas que se unen a CD70 y métodos de uso de las mismas | |
| Acharya et al. | Interleukin-17A promotes CD8+ T cell cytotoxicity to facilitate West Nile virus clearance | |
| Deckers et al. | Innate immune cells in asthma | |
| US20230374133A1 (en) | Anti-tcr antibody molecules and uses thereof | |
| JP7289562B2 (ja) | 抗ｂｃｍａ単一ドメイン抗体及びその適用 | |
| US20230197187A1 (en) | Selective peptide antagonists | |
| JP2018184428A5 (OSRAM) | ||
| US11111288B2 (en) | Conditionally active chimeric antigen receptors for modified t-cells | |
| KR20210117260A (ko) | 입양 세포 요법을 사용한 치료방법 | |
| JP2013506425A5 (OSRAM) | ||
| Paroli et al. | The role of interleukin-17 in juvenile idiopathic arthritis: from pathogenesis to treatment | |
| CN120943971A (zh) | 用于刺激自然杀伤细胞的组合物和方法 | |
| KR20250143365A (ko) | Tcr에 결합하는 다기능성 분자 및 이의 용도 | |
| Hirahara et al. | Immune cell-epithelial/mesenchymal interaction contributing to allergic airway inflammation associated pathology | |
| Lamers et al. | Brain-specific HIV Nef identified in multiple patients with neurological disease | |
| Le Floc’h et al. | Blocking common γ chain cytokine signaling ameliorates T cell–mediated pathogenesis in disease models | |
| Gavriil et al. | Engineering solutions for mitigation of chimeric antigen receptor T-Cell dysfunction | |
| Zhang et al. | Development of BCMA-targeted bispecific natural killer cell engagers for multiple myeloma treatment | |
| US20240043475A1 (en) | Peptide conjugates | |
| JP2024538064A (ja) | ミクログリア活性化を抑制するための方法 |